Litcius/Paper detail

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial

Vanita R. Aroda, Jens Aberle, Lars Bardtrum, Erik Christiansen, Filip K. Knop, Sanaz Gabery, Sue D. Pedersen, John B. Buse

2023The Lancet108 citationsDOI

Topics & Concepts

SemaglutideMedicineType 2 diabetesInternal medicineDiabetes mellitusPhysical therapyEndocrinologyLiraglutideDiabetes Treatment and ManagementBariatric Surgery and OutcomesMetabolism, Diabetes, and Cancer
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial | Litcius